

Bereskin & Parr



Barristers and Solicitors/Patent and Trade Mark Agents
Practice Restricted to Intellectual Property Law

April 9, 2001

Anita Nador B.A. (Molec. Biophys./Biochem), LL.B.
416 957 1684 anador@bereskinparr.com

Our Reference: 11014-24

The Commissioner of Patents
and Trademarks
Washington, D.C.
U.S.A. 20231

Dear Sir:

Re: U.S. Regular Patent Application
Claiming Priority from U.S. Provisional Patent Application No. 60/195,456
Entitled: Immunogenic Peptides Derived From Prostate-
Specific Antigen (PSA) and Uses Thereof
Inventors: Artur Pedyczak, Pele Chong, Charles D.Y. Sia


Applicants are submitting the above-identified patent application for filing at the United States Patent and Trademark Office.

Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.

In accordance with the requirements of 37 C.F.R. 1.821-1.825 the undersigned verifies that the paper form of the Sequence Listing and the computer readable form of the Sequence Listing are the same.

Respectfully submitted

ARTHUR PEDYCZAK, PELE CHONG
CHARLES D.Y. SIA


Anita Nador
Registration No. 47,366
BERESKIN & PARR
(Agents for the Applicants)

Enclosure

SEQUENCE LISTING

<110> Chong, Pele

Pedyczak, Artur

Sia, Charles Dwo Yuan

<120> Immunogenic Peptides Derived from Prostate-Specific Antigen (PSA) and Uses Thereof

<130> 11014-24

<150> US 60/195,456

<151> 2000-04-10

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 8

<212> PRT

<213> Artificial

<220>

<223> CLP313

<400> 1

Met Trp Val Pro Val Val Phe Leu
1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial

<220>

<223> CLP314

<400> 2

Val Leu Val His Pro Gln Trp Val Leu
1 5

<210> 3

SEQUENCE LISTING

<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP316
<400> 3

Lys Leu Gln Cys Val Asp Leu His Val
1 5

<210> 4
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP315
<400> 4

Asp Leu Pro Thr Gln Glu Pro Ala Leu
1 5

<210> 5
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP317
<400> 5

Asp Leu His Val Ile Ser Asn Asp Val
1 5

<210> 6
<211> 9
<212> PRT
<213> Artificial

<220>
<223> CLP320
<400> 6

Pro Leu Tyr Asp Met Ser Leu Leu Lys
1 5

<210> 7
<211> 24
<212> DNA
<213> Artificial

<220>
<223> CLP313
<400> 7
atgtgggtcc cgggtgtctt cctc

24

<210> 8
<211> 27
<212> DNA
<213> Artificial

<220>
<223> CLP314
<400> 8
gttctgggtgc acccccagtg ggtcctc

27

<210> 9
<211> 27
<212> DNA
<213> Artificial

<220>
<223> CLP316
<400> 9
aaacttcagt gttgggacct ccatgtt

27

<210> 10
<211> 27
<212> DNA
<213> Artificial

<220>
<223> CLP315
<400> 10
gacctgacca cccaggagcc agcactg

27

<210> 11

<211> 27

<212> DNA

<213> Artificial

<220>

<223> CLP317

<400> 11
gacctccatg ttatttccaa tgacgtg

27

<210> 12

<211> 27

<212> DNA

<213> Artificial

<220>

<223> CLP320

<400> 12
ccgctctacg atatgagcct cctgaag

27